5 ms·

Also,in France: https://www.mediterranee-infection.com/covid-19/ https://www.mediterranee-infection.com/covid-19/

• tonfa 7y ago
  Tho they've focused mostly on care instead of the science (they don't believe in randomized trials), and it's going to be hard to know if the treatment is efficient from those (the EU and Michigan studies should help figuring that out).
  • vanniv 7y ago
    In the absence of other viable treatments, the efficiency isn't really important. Frankly, if it is only modestly effective, it should still be given to everyone without contraindications. Efficiency only becomes important in a year or two when there are competing therapies. When the choices are Chloroquine or Hopes and Prayers, Chloroquine is the obvious choice (for those that don't have the contraindications, of course -- for those patients, you'd need more evidence to know that the benefits outweighed the risks)